Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we repor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Main Authors: Conticello, Concetta, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Sapienza, Giuseppe, Leotta, Valerio, Parisi, Marina Silvia, Markovic, Uros, Garibaldi, Bruno, Leotta, Salvatore, Cotzia, Emilia, Innao, Vanessa, Mannina, Donato, Neri, Santo, Musso, Maurizio, Scalone, Renato, Cangialosi, Clotilde, Acquaviva, Francesco, Cardinale, Giovanni, Merenda, Anxur, Maugeri, Cinzia, Uccello, Giuseppina, Poidomani, Massimo, Longo, Giuseppe, Carlisi, Melania, Tibullo, Daniele, Di Raimondo, Francesco
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617295/
https://ncbi.nlm.nih.gov/pubmed/31248142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8060877
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares